HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate.

Abstract
Morbidity and mortality in patients with T large granular lymphocyte (T-LGL) leukemia result from infections acquired during severe neutropenia. Optimum treatment for severe neutropenia remains undefined. We conducted an uncontrolled but prospective study of low-dose oral methotrexate, up to 10 mg/m2 weekly, in 10 patients with this disease. Therapeutic response was assessed by serial clinical evaluations and laboratory determinations including complete blood counts, lymphocyte phenotyping, and T-cell receptor gene rearrangement studies. A partial response was defined as a sustained increase in neutrophil count greater than 500/microL. A complete clinical remission was defined as achievement of a normal complete blood count and CD3+ LGL count. Previous prednisone treatment in eight of these patients had produced one clinical remission and four partial responses; tapering of prednisone in each of these patients resulted in recurrence of severe neutropenia. Five patients in this study received both methotrexate and tapering doses of prednisone. Complete clinical remissions on methotrexate were observed in five patients; an additional patient had a partial response. Molecular analyses of T-cell receptor gene rearrangement could not detect the abnormal clone in three of five patients achieving a complete clinical remission. Two weeks to 4 months of therapy were needed before attaining a neutrophil count greater than 500/microL. Complete and partial responses have been maintained on therapy, with a follow-up period ranging from 1.3 to 9.6 years. Low-dose oral methotrexate therapy is an effective treatment for some patients with LGL leukemia.
AuthorsT P Loughran Jr, P G Kidd, G Starkebaum
JournalBlood (Blood) Vol. 84 Issue 7 Pg. 2164-70 (Oct 01 1994) ISSN: 0006-4971 [Print] United States
PMID7919331 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Methotrexate
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Communicable Diseases (complications)
  • Dose-Response Relationship, Drug
  • Female
  • Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
  • Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
  • Humans
  • Immunophenotyping
  • Leukemia, Lymphoid (drug therapy)
  • Lymphocyte Count
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Neutrophils
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: